Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Kanova logo — Pioneering advanced therapies in immuno-oncology and autoimm...

Kanova

Pioneering advanced therapies in immuno-oncology and autoimmune diseases.

Founded 2015 2-10 employees Series B Total: $215.00M Biopharma, Health and Wellness +1

General Information

Company Name Kanova
Founded Year 2015
Employees 2-10
Industries Biopharma, Health and Wellness, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Kanova. To contact Kanova, visit en.kanovabiopharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Kanova compare?

A PDF of Kanova and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Kanova soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Kanova

Kanova is a biopharmaceutical company founded in 2015 that focuses on developing therapeutic antibodies and innovative combination therapies in immuno-oncology and autoimmune diseases. The company's slogan, "Pioneering advanced therapies in immuno-oncology and autoimmune diseases," reflects its commitment to cutting-edge medical solutions. In its latest funding round, Kanova secured a significant CNY100.00M Series B investment on 25 July 2023. The investment was led by prominent venture capital firms including Northern Light Venture Capital, Tsinghua Venture Capital, CD Capital, Life Garden Venture Capital, Yangzhou Fengsheng Investment, and ShenZhen GTJA Investment Group. With its focus on the biopharma, health and wellness, and pharmaceutical industries, Kanova is positioned for growth and innovation in the rapidly evolving field of medical therapeutics.

Business keywords: biopharmaceutical, therapeutic antibodies, immuno-oncology, autoimmune diseases, advanced therapies, immunotherapy, oncology, cancer treatment, immunology, drug development

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B CNY100.00M 6
Northern Light Venture Capital Tsinghua Venture Capital CD Capital
Northern Light Venture Capital, Tsinghua Venture Capital +4
25 Jul 2023
Series B Undisclosed 4
Tsinghua Venture Capital Sino-Singapore Capital 3H Health Investment
Tsinghua Venture Capital, Sino-Singapore Capital +2
13 Jul 2021
Series A CNY115.00M -
26 Nov 2018

Kanova Alternatives & Competitors

View All Alternatives
Kanova vs
Antharis Therapeutics, Inc.
Antharis Therapeutics, Inc. United States

Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting-edge trea...

18 employees
Biopharma, Biotechnology
Kanova vs
Harbour BioMed
Harbour BioMed United States

Healthy Life · Breakthrough Medicines

IPO
113 employees
Biopharma, Biotechnology
Kanova vs
Apexigen
Apexigen United States

Creating Transformative Immunotherapies for Patients with Cancer

Post-IPO Equity
11 employees
Biopharma, Biotechnology
Also compare with: Kanova vs Symphogen Symphogen View all alternatives

FAQ About Kanova

Pioneering advanced therapies in immuno-oncology and autoimmune diseases.
Kanova was founded in 2015.
Kanova operates in Biopharma, Health and Wellness and Pharmaceutical. Its work centres on biopharmaceutical, therapeutic antibodies, immuno-oncology and autoimmune diseases.
Kanova has approximately 2-10 employees.
Kanova has completed 3 funding rounds, raising a total of $215.00M. The latest funding stage is Series B.
Top alternatives and competitors to Kanova include Antharis Therapeutics, Inc., Harbour BioMed, Apexigen, ImCheck Therapeutics, Xilio Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kanova and Antharis Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kanova, https://bouncewatch.com/company/kanova, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes